Cookies on this site

The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

Sponsored by the University of Oxford and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), the trial will involve 51 healthy adults aged 18–55 years in Kintampo North Municipality and Kintampo South District, in Central Ghana.

Lassa fever is an acute viral illness caused by the Lassa virus. The World Health Organization (WHO) identifies Ghana and several other West African countries, including Nigeria, as countries where the disease is endemic. Sporadic cases have been reported in Ghana since 2011, with the country recording its largest outbreak in 2023.

This trial follows an earlier first-in-human Phase 1 study of ChAdOx1 LassaJ conducted by the Oxford Vaccine Group in the United Kingdom. The vaccine was developed by scientists at the Oxford Vaccine Group and Pandemic Sciences Institute, both at the University of Oxford, using the same vaccine technology platform as the Oxford-AstraZeneca COVID-19 vaccine.
Prof. Kwaku Poku Asante, Director of KHRC and one of the investigators of the trial, emphasised the importance of the study in strengthening health security in West Africa and building the Centre’s capacity to conduct early-stage clinical trials.

“This is the second Phase 1 trial at KHRC, and this one is particularly important. We have all heard about Lassa fever and the outbreaks in the region. Lassa fever may not be an outbreak in Ghana at this moment, but it is prevalent in places like Nigeria, and Ghanaians and Nigerians interact and travel across the border every day. This makes the study very important,” he said.

He added that the trial protocol had undergone the required regulatory reviews in Ghana and the UK before it began.

On his part, the Principal Investigator of the study at KHRC, Dr Seyram Kaali, reiterated his team’s commitment to conducting the study to the highest ethical and regulatory standards.

Professor Maheshi Ramasamy, the Chief Investigator of the study said: “We are absolutely thrilled to see the first participant vaccinated in the ViTtaL-02 Lassa fever trial in Ghana. This is a hugely exciting milestone and a wonderful moment for everyone who has worked so hard to bring the study to this point.

We are especially grateful to our colleagues at KHRC, whose dedication, expertise and tremendous teamwork have made this achievement possible, but most of all to our study participants, whom without, we would not be able to progress our work in developing a vaccine against Lassa fever."

“More than 50 years after Lassa fever was first identified, communities across West Africa are still waiting for a licensed vaccine,” said Dr Katrin Ramsauer, Lassa Disease Programme Lead at CEPI.

“The launch of this trial in Ghana is an important step towards changing that, while also further establishing research capacity in West Africa.”

“Seeing a Lassa fever vaccine trial begin here in West Africa, led by West African scientists, is a proud moment for our region,” said Dr Virgil Lokossou, Director of Healthcare Services at West African Health Organisation (WAHO). “Through the Lassa fever Coalition, our Member States are preparing now so that, once a vaccine is proven safe and effective, it can reach the communities that need it most.”

As a research Centre under the Ghana Health Service, KHRC has successfully conducted clinical trials for over 30 years, from early-stage studies of vaccines or medicines in humans to larger trials assessing safety, effectiveness and impact in real-world settings. The Centre has a well-equipped clinical trial unit to manage medical emergencies. 

Recruitment is underway, and interested volunteers will be screened to determine their eligibility. The 51 participants will be assigned to groups receiving different combinations of the vaccine candidate and a placebo, which contains no active vaccine ingredient. Each participant will be followed for one year to monitor safety and assess their immune response to the vaccine.

Learn more about KHRC’s clinical trials research

Similar stories

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Lymph Node Research UK launches with national network of ten specialist research centres

Oxford, 16 June 2026: A new £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease has launched, bringing together ten specialist centres across the country.

Similar stories

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Lymph Node Research UK launches with national network of ten specialist research centres

Oxford, 16 June 2026: A new £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease has launched, bringing together ten specialist centres across the country.